Situation
Managing chronic conditions often presents significant challenges for patients. These challenges range from affordability barriers to medication adherence. The World Health Organization (WHO) estimates that 50 percent of patients with chronic diseases globally do not adhere to their prescribed treatment, which can lead to repeated hospitalization incidents
Low adherence is a leading problem worldwide, especially in patients with chronic diseases that require long-term management, such as diabetes mellitus, hypertension, cardiovascular disease, cancer, multiple sclerosis and migraine. Patient Support Programs (PSPs) have demonstrated significant benefits globally, with enrolled patients showing improvement in treatment adherence rates. PSPs are essential to bridging gaps in access. They improve adherence and also improve healthcare outcomes by providing financial assistance, educational resources, and personalized support.
Solution
A top pharmaceutical firm, in collaboration with Axios International, launched a patient support program (PSP) in 2016 with the aim of enhancing treatment adherence for Multiple Sclerosis (MS) and Migraine. The PSP optimizes the therapeutic outcomes, and empowers patients and their families in managing chronic conditions effectively. The PSP’s design leverages Axios International’s expertise in delivering tailored patient support solutions, with key components such as personalized care plans that utilized the Patient Needs Assessment Tool (PNAT) to conduct thorough evaluations of each patient’s challenges and needs. This data-driven approach allows for the creation of personalized Adherence Treatment Plans to achieve better outcomes. It offers a wide range of support, including disease and treatment education, to empower patients by providing them with emotional and psychosocial support. The PSP additionally provides remote care services, insurance coordination to streamline access to prescribed treatments, pre-treatment testing and ongoing monitoring to ensure adherence and alignment with therapy plans. The PSP addresses the World Health Organization’s (WHO) five dimensions of adherence—social and economic, therapy-related, patient-related, healthcare team and system, and condition-related—to create a robust, multilayered support structure.
Results
Since its launch, the PSP has made a significant impact by benefitting over 1,055 patients in the UAE and Kuwait. By addressing key barriers and providing personalized services, the PSP has enabled patients to adhere to and complete their treatment plans, leading to better therapeutic outcomes. The average compliance rate stands at 98.4 percent with an average dropout rate of 0.67 percent. Patients and their families have been supported by tailored services that address both medical and psychosocial needs. Additionally, the PSP has effectively mitigated financial and logistical barriers, ensuring patients receive consistent and comprehensive care outside of traditional hospital settings.
To learn more about our services, write to axios@axiosint.com
